Cellectar FY2022 net loss $28.6M ($4.05/share); cash $19.9M, runs to Q4 2023

Cellectar Biosciences, Inc.

Net loss $28.6M ($4.05/share) vs $24.1M ($4.35/share) in 2021.
Cash $19.9M at 12/31/22 vs $35.7M at 12/31/21; operating cash used $25.2M; funds into Q4 2023.
R&D $19.2M (up $1.6M); G&A $9.5M (up $3.0M) from prior year.
Lawsuit resolved with WARF; non-exclusive license secured; all claims against Drs. Weichert and Pinchuk dismissed.
Appointed Shane Lea as CCO and Dr. Andrei Shustov as SVP Medical; positive clinical data including CNS lymphoma complete response.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.